It is recognized that iron overload is associated with excess mortality in HIV/AIDS, and that this may be due to iron acting as an HIV-1 transcriptional activator. In vitro evidence using iron chelators suggests that therapeutic iron depletion may be beneficial in HIV-1 infection. We describe the clinical course of a Caucasian man with hereditary haemochromatosis and HIV infection where a significant drop in HIV viral load accompanied venesection over an 18-month period in the absence of HAART. We propose that further research should be undertaken to explore the relationship between HIV viral load and serum iron markers in hereditary haemochromatosis, with a view to evaluating the therapeutic benefit of venesection on HIV viral load in this setting.
References
1.
SalhiY., CostagliolaD., RebullaP.Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients. J Acquir Immune Defic Syndr Hum Retrovirol1998; 18: 473–478.
2.
GordeukV.R., OnojobiG., SchneiderM.F.The association of serum ferritin and transferrin receptor concentrations with mortality in women with human immunodeficiency virus infection. Haematologica2006; 91: 739–743.
3.
de MonyéC., KarcherD.S., BoelaertJ.R., GordeukV.R.Bone marrow macrophage iron grade and survival of HIV-seropositive patients. AIDS1999; 13: 375–380.
4.
McDermidJ.M., JayeA., Schim van der LoeffM.F.Elevated iron status strongly predicts mortality in West African adults with HIV infection. J Acquir Immune Defic Syndr2007; 46: 498–507.
5.
FriisH., GomoE., NyazemaN.Iron, haptoglobin phenotype, and HIV-1 viral load: a cross-sectional study among pregnant Zimbabwean women. J Acquir Immune Defic Syndr2003; 33: 74–81.
6.
NabelG., BaltimoreD.An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature1987; 326: 711–713.
7.
FederJ.N., GnirkeA., ThomasW.A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet1996; 13: 399–408.
8.
KupkaR., MsamangaG.I., MugusiF., PetraroP., HunterD.J., FawziW.W.Iron status is an important cause of anemia in HIV-infected Tanzanian women but is not related to accelerated HIV disease progression. J Nutr2007; 137: 2317–2323.
9.
SappeyC., BoelaertJ.R., Legrand-PeolsS., ForceilleC., FavierA., PietteJ.Iron chelation decreases NF-κB and HIV type 1 activation due to oxidative stress. AIDS Res Hum Retroviruses1995; 11: 1049–1061.
10.
XiongS., SheH., TakeuchiH.Signaling role of intracellular iron in NF-κB activation. J Biol Chem2003; 278: 17646–17654.
DrakesmithH., PrenticeA.Viral infection and iron metabolism. Nat Rev Microbiol2008; 6: 541–552.
13.
DrakesmithH., ChenN., LedermannH., ScreatonG., TownsendA., XuX.N.HIV-1 Nef down-regulates the hemochromatosis protein HFE, manipulating cellular iron homeostasis. Proc Natl Acad Sci U S A2005; 102: 11017–11022.
14.
PortoG., CardosoC.S., GordeukV.Clinical and genetic heterogeneity in hereditary haemochromatosis: association between lymphocyte counts and expression of iron overload. Eur J Haematol2001; 67: 110–118.
15.
ArosaF.A., da SilvaA.J., GodinhoI.M.Decreased CD8-p56lck activity in peripheral blood T-lymphocytes from patients with hereditary haemochromatosis. Scand J Immunol1994; 39: 426–432.
16.
GeorgiouN.A., van der BruggenT., OudshoornM., NettetH.S., MarxJ.J., van AsbeckB.S.Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. J Infect Dis2000; 181: 484–490.
17.
CostagliolaD.G., de MontalembertM., LefrereJ.J.Dose of desferrioxamine and evolution of HIV-1 infection in thalassaemic patients. Br J Haematol1994; 87: 849–852.
18.
NielsenP., DegenO., BrummerJ., GabbeE.E.Long-term survival in a patient with AIDS and hereditary haemochromatosis. Eur J Haematol1999; 63: 202–204.
